Equity Profile

CRMD

CorMedix Inc.

Health CarePharmaceuticals$662.1M

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative products for the treatment of infectious diseases and other medical conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.43

Revenue Growth

Revenue growth signals the company's ability to expand its market presence and product adoption, crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRMD Q2-2026 Earnings Preview

Context

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative products for the treatment of infectious diseases and other medical conditions. With a market cap of $1 billion, the company operates in the health care sector, which is increasingly important as the demand for effective treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+37.26%

Avg Stock Reaction

-1.74%

Last Quarter Recap

In Q1 2026, CorMedix reported an EPS of $0.43, surpassing expectations by 24.64%. The stock reacted positively, gaining 5.73% the following day.

Management Promises & Guidance

Continued focus on product development and market expansion.
Commitment to improving operational efficiencies.
Plans to enhance partnerships with healthcare providers.

Expectations

Wall Street Expectations

Investors are generally optimistic about CorMedix's upcoming earnings, especially given the strong EPS surprise last quarter. However, there is uncertainty regarding revenue growth and management's future guidance.

Bull Case

If CorMedix continues to beat EPS expectations and shows strong revenue growth, it could signal robust demand for its products, leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock value, as seen in previous quarters.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.43

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth signals the company's ability to expand its market presence and product adoption, crucial for long-term success.

Market Reaction to Earnings Surprise

N/A

Understanding how the stock has reacted to past earnings surprises can provide insight into potential market behavior this quarter.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to the previous quarter's $0.43?

Given the company's recent strong performance, the market will be closely watching for continued profitability.

What guidance will management provide regarding revenue growth moving forward?

Investors need clarity on future revenue expectations to gauge the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate CorMedix's ability to sustain high EPS growth, given its recent performance and market positioning.

Supporting Evidence

The company has consistently beaten EPS estimates, with an 88% beat rate over the last eight quarters.

Options pricing suggests a larger move than historical averages, indicating potential for a surprise.

The stock's recent positive momentum could reflect underlying strength not fully appreciated by the market.

Key Risk

If the EPS comes in below $0.30, it could undermine the bullish sentiment and lead to a reevaluation of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CorMedix can sustain its recent earnings momentum and provide credible growth forecasts.

Bull Confirmed If

An EPS of $0.50 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.30 would raise concerns about profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±22.51%

Historical Avg

±17.1%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty around the earnings report.

Options are pricing ±22.5% while CRMD has averaged ±17.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (50K)P/C Ratio: 0.11Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CorMedix beats expectations, history suggests the stock could rise by around 2.06% on the first day, confirming positive market sentiment.

In-Line / Cautious

If the results are in line with expectations, the stock may experience limited movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 11.52%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product development timelines and expected market launches.
2Management's commentary on competitive positioning and market share.
3Insights into operational efficiencies and cost management strategies.
4Guidance on revenue expectations for the next quarter and beyond.
5Responses to analyst questions regarding potential risks and challenges.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative products for the treatment of infectious diseases and other medical conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.43

Revenue Growth

Revenue growth signals the company's ability to expand its market presence and product adoption, crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRMD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+37.26%

Avg Stock Reaction

-1.74%

Last Quarter Recap

In Q1 2026, CorMedix reported an EPS of $0.43, surpassing expectations by 24.64%. The stock reacted positively, gaining 5.73% the following day.

Management Promises & Guidance

Continued focus on product development and market expansion.
Commitment to improving operational efficiencies.
Plans to enhance partnerships with healthcare providers.

Expectations

Wall Street Expectations

Bull Case

If CorMedix continues to beat EPS expectations and shows strong revenue growth, it could signal robust demand for its products, leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock value, as seen in previous quarters.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.43

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth signals the company's ability to expand its market presence and product adoption, crucial for long-term success.

Market Reaction to Earnings Surprise

N/A

Understanding how the stock has reacted to past earnings surprises can provide insight into potential market behavior this quarter.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to the previous quarter's $0.43?

Given the company's recent strong performance, the market will be closely watching for continued profitability.

What guidance will management provide regarding revenue growth moving forward?

Investors need clarity on future revenue expectations to gauge the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate CorMedix's ability to sustain high EPS growth, given its recent performance and market positioning.

Supporting Evidence

The company has consistently beaten EPS estimates, with an 88% beat rate over the last eight quarters.

Options pricing suggests a larger move than historical averages, indicating potential for a surprise.

The stock's recent positive momentum could reflect underlying strength not fully appreciated by the market.

Key Risk

If the EPS comes in below $0.30, it could undermine the bullish sentiment and lead to a reevaluation of the company's growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CorMedix can sustain its recent earnings momentum and provide credible growth forecasts.

Bull Confirmed If

An EPS of $0.50 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.30 would raise concerns about profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±22.51%

Historical Avg

±17.1%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating heightened uncertainty around the earnings report.

Options are pricing ±22.5% while CRMD has averaged ±17.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (50K)P/C Ratio: 0.11Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CorMedix beats expectations, history suggests the stock could rise by around 2.06% on the first day, confirming positive market sentiment.

In-Line / Cautious

If the results are in line with expectations, the stock may experience limited movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 11.52%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product development timelines and expected market launches.
2Management's commentary on competitive positioning and market share.
3Insights into operational efficiencies and cost management strategies.
4Guidance on revenue expectations for the next quarter and beyond.
5Responses to analyst questions regarding potential risks and challenges.